We're getting a head start on the new year with the publication of 2016 Oncology Nursing Drug Handbook by Gail M. Wilkes and Margaret Barton-Burke. Written especially for nurses caring for patients with cancer and updated annually, it expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation.
What else makes 2016 Oncology Nursing Drug Handbook special?
- Offers valuable information on effective symptom management, patient education, and chemotherapy administration
- Includes a simplified chapter on molecular and biological targeted therapy that incorporates new information about immunotherapy
- Provides new indications and the most important and common side effects
New drugs include: blinatumomab (Blincyto), ceftazidime/avibactam (Avycaz), ceftolozane/tazobactam (Zerbaxa), dalbavancin (Dalvance), dinutuximab (Unituxin), filgrastim-sndz (Zarxio), isavuconazonium sulfate (Cresemba), lanreotide (Somatuline Depot Injection), lenvatinib (Lenvima), naloxegol (Movantik), Netupitant/palonosetron (Akynzeo), nivolumab (Opdivo), olaparib (Lynparza), oritavancin (Orbactiv), palbociclib (Ibrance), panobinostat (Farydak), sonidegib (Odomzo), and tedizolid phosphate (Sivextro).
Can't wait to learn more? Visit our website.